Protocol Ledger

NCT05998759 · Phase II · RECRUITING

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Interventional Phase II clinical trial protocol NCT05998759 sponsored by Beijing Hospital in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-02 Enrollment: 296 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05998759
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)296 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05998759
Protocol FieldVerified Registry Value
NCT IdentifierNCT05998759
Consolidated Lead SponsorBeijing Hospital
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment296 participants (ESTIMATED)
Registered Start Date2023-12-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05998759
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI